News Archives - Page 3 of 3 - Newcells Biotech

Newcells Biotech

iPSC derived retinal organoids: A Promising Tool for Modelling Retinitis Pigmentosa

Newcells Biotech technology: the fight against antibacterial resistance

Newcells Biotech Win Phase I of CRACK IT Challenge 29: ImmuLiver – Securing £99,711 Funding

Looking Forward: A Year in Review

Newcells Head to Boston

ESTIV 2018 International Congress

Induced Pluripotent Stem Cells: A Powerful Tool for Drug Discovery & Safety Screening

Retinal Organoids: Mini Organs Add a New Dimension to our Understanding of the Eye

Leading Drug Transport and Drug Toxicity Expert, Dr Colin Brown joins Newcells Biotech

22nd North American ISSX Meeting - Montréal, Canada (15th-19th July)

BY Newcells Biotech

September 28, 2015June 13, 2018

Newcells Biotech Ltd completes a licensing agreement with ID Pharma Co. Ltd for induced pluripotent stem cell technologies

Newcells Biotech Ltd has signed a patent license agreement with ID Pharma Co., Ltd to license and commercialise ID Pharma Co., Ltd patented technologies in the Sendai virus vectors for reprogramming cells to induced pluripotent stem cells (iPSCs).

BY Newcells Biotech

September 9, 2015June 13, 2018

Newcells Biotech Ltd completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies

Newcells Biotech Ltd has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialise Kyoto University’s patented technologies in the field of induced pluripotent stem cells (iPSCs).